The trial met its primary endpoint, demonstrating that semaglutide 7.2 mg led to significantly greater weight loss at week 72 compared to placebo
Feb 14, 2026 Your first GLP-1 injection does not have to feel like defusing a bomb
Cardiovascular Health: Given its cardiovascular benefits, Tirzepatide may be recommended for individuals with specific cardiovascular risk factors
Possible reasons include low calories, low protein, dehydration, electrolyte imbalance, poor sleep, rapid weight loss, dose escalation, and micronutrient issues
Frequency depends on your individual needs, but many patients benefit from weekly or bi-weekly treatments initially, then monthly for maintenance
USD 39.95 Prices may be subject to local taxes which are calculated during checkout Similar content being viewed by others References Smith, T